Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Evolutionary Anti-Starvation Mechanism May Now Drive Obesity Epidemic

Scientists in the United States suggest how a molecular mechanism that may have helped to stop our ancestors from starving might now be contributing to the obesity epidemic. Studies headed by a team at the NYU School of Medicine found that a protein located on

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Scientists in the United States suggest how a molecular mechanism that may have helped to stop our ancestors from starving might now be contributing to the obesity epidemic. Studies headed by a team at the NYU School of Medicine found that a protein located on the surface of fat cells acts to stop the breakdown of stored fat in response to different stressors.

“We discovered an anti-starvation mechanism that has become a curse in times of plenty because it sees cellular stress created by overeating as similar to stress created by starvation—and puts the brakes on our ability to burn fat,” said Ann Marie Schmidt, MD, the Dr. Iven Young professor of endocrinology at NYU School of Medicine, who is corresponding author of the researchers’ published paper in Cell Reports, which is titled, “A Receptor of the Immunoglobulin Superfamily Regulates Adaptive Thermogenesis.”

An animal’s ability to store and use nutrients is dependent upon a precise balance between energy intake and energy expenditure, the authors wrote. “Yet, hoarding energy is a double-edged sword, albeit, salutary in nutrient deprivation; in over-feeding, excess energy storage confers susceptibility to obesity and type 2 diabetes.”

White adipose tissue (WAT, or white fat), and brown adipose tissue (BAT, or brown fat) in mammals store energy in the form of triglycerides and release fatty acids and glycerol in response to cues by the sympathetic nervous system. “Whereas WAT releases fatty acids into the circulation, BAT preferentially oxidizes fatty acids and dissipates energy through uncoupled respiration and the production of heat,” the researches further explained.

The authors suggest that evolution devised an anti-starvation mechanism that helped animals to efficiently use food to fuel their cellular activity and recover from injury. Studies now suggest that integral to this mechanism is the immunoglobulin superfamily molecule, the receptor for advanced glycation end (RAGE) products. RAGE binds to specific molecules that accumulate in metabolic stress, and which are linked with diabetes and inflammation. However, the team noted, more recent evidence suggests that these molecules, and RAGE itself, are also present in human and mouse fat tissue. The hormone mechanism also links in by signaling for the conversion of fat into energy either for flight from danger, or to generate heat when the body gets cold. The idea is that that RAGE effectively acts to block fat burning when we starve, freeze, become injured, or panic, and, potentially, when we overeat. This concept fits in with the authors’ own recent finding that mice engineered to lack Ager, the gene encoding RAGE, are protected from obesity and insulin resistance when fed a high-fat diet (HFD).

Through their newly reported studies, Schmidt and colleagues showed that mice engineered with adipose-specific deletion of Ager were also significantly protected from HFD-induced obesity and insulin resistance than control animals, and were better able to control body temperature during a cold challenge. Mice lacking RAGE in their fat cells gained up to 75% less weight after three months on a high-fat diet than mice that retained RAGE, despite equal amounts of food consumption and physical activity. Transplanting fatty tissue lacking RAGE into normal mice also led to decreased weight gain when the animals were then fed a high-fat diet. In both sets of experiments RAGE deletion from fat cells effectively released braking mechanisms that held back energy expenditure, so the animals could ramp up energy expenditure when fed a high-fat diet, which helped to reduce weight gain.

The researchers aim to optimize their RAGE inhibitors and test whether the molecules can help to stop weight regain in bariatric surgery patients and those undergoing medical weight loss programs. Putting lost weight back on isn’t uncommon for even the most successful dieters. A 2016 study found that contestants from America’s Greatest Loser piled the pounds back on after the show ended. “Because RAGE evolved out of the immune system, blocking it may also reduce the inflammatory signals that contribute to insulin resistance driving diabetes,” said Schmidt. “Further, such treatments may lessen the system-wide inflammation linked to risk for atherosclerosis, cancer, and Alzheimer’s disease.”

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
02How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →